The Neuroendocrine Unit at Massachusetts General Hospital is offering a 12-month long clinical research study for women between the ages of 18 and 30 years old who have stopped having menstrual periods. The purpose of the research is to evaluate the effect of a drug called romosozumab, followed by a drug called zoledronic acid, in addition to estrogen and progesterone, on bone density and bone strength in this population. Participants are compensated
up to $1550. If you are interested in participating or learning more about our studies, please fill out our quick questionnaire at the link below. You can also contact Zeena Joseph at zjoseph [at] mgh.harvard.edu or call 617-724-5406 for more information.
The link is below; please feel free to forward it along to anyone you think might be interested!
https://rally.massgeneralbrigham.org/study/bone_health_study_e2romo